Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
A 67-Year-Old Woman with Progressive Tingling Sensations and Imlalance
Neurol 100:151-157, Horta,L.F.B.,et al, 2023
A 60-Year Old Man with Asymmetric Weakness and Persistent Fever
Neurol 100:530-536, Zheng,Y.,et al, 2023
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Atypical Presentation of Primary Angiitis of Central Nervous System Responsive to Rituximab
Stroke 53:e490-e494, Kesav, P.,et al, 2022
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Neurologic IgG4-Related Disease
Neurohospitalist 9:118-119, Topiwala, K.,et al, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 379:2452-2461, Case 39-2018, 2018
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Overview of IgG4-related Disease
UptoDate, July, Moutsopoulos,H.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Rituximab Treatment for Autoimmune Limbic Encephalitis in an Institutional Cohort
Neurol 86:1683-1691,1655, Lee, W.J.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Treatment Outcomes with Rituximab in 100 Patients with Neuromyelitis Optica
JAMA Neurol 72:989-995, Kim, S.H.,et al, 2015
Treatment of Primary CNS Vasculitis with Rituximab: Case Report
Neurol 82:1287-1288, Salvarani, C.,et al, 2014
Effect of Rituximab in Patients with Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy
JAMA Neurol 71:896-900, Irani, S.R.,et al, 2014
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Long-lasting Treatment Effect of Rituximab in MuSK Myasthenia
Neurol 78:189-193, Diaz-Manera,J.,et al, 2012
Rituximab Monotherapy for Patients With Recurrent Primary CNS Lymphoma
Neurol 76:929-930, Batchelor,T.T.,et al, 2011
Rituximab in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature
JNNP 82:306-308, Benedetti,L.,et al, 2011
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Random skin biopsy and bone marrow biopsy for diagnosis of intravascular large B cell lymphoma
Ann Hematol 90:417-421, Matsue, K.,et al, 2011
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Neurological disturbances caused by intravascular lymphomatosis
Brain Nerve 63:443-449, Mizutani, T., 2011
Encephalitis Associated with Glutamic Acid Decarboxylase Autoantibodies in a Child A Treatable Condition?
Arch Neurol 68:1065-1068, Korff, C.M.,et al, 2011
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Arch Neurol 68:1156-1164, Clifford, D.B.,et al, 2011
Clinicopathologic Conference, Limbic Encephaitis with Antibodies to Leucine - Rich Glioma - inactivated 1 (LGI 1).
NEJM 365:1825-1833, Case 34-2011, 2011
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Posterior Reversible Encephalopathy Syndrome After Rituximab Infusion in Neuromyelitis Optica
Neurol 74:1471-1473, S�nchez-Carteyron,A., et al, 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Lymphomatoid Granulomatosis Involving Central Nervous System Successfully Treated With Rituximab alone
Arch Neurol 65:662-665, Ishiura,H.,et al, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Response of Anti-NMDA Receptor Encephalitis Without Tumor to Immunotherapy Including Rituximab
Neurol 71:1921-1923, Ishiura,H.,et al, 2008
Treatment of Neuromyelitis Optica with Rituximab; Retrospective Analysis of 25 Patients
Arch Neurol 65:1443-1448, Jacob,A.,et al, 2008
Progressive Multifocal Leukoencephalopathy After Rituximab in a Case of Non-Hodgkin Lymphoma
Neurol 69:704-706, Kranick,S.M.,et al, 2007
Limbic Encephalitis and Variants: Classification, Diagnosis and Treatment
Neurologist 13:261-271, Tuzun,E. &Dalmau,J., 2007
Rapidly Fatal Acanthamoeba Encephalitis and Treatment of Cryoglobulinemia
Emerg Infect Dis 13:469-471, Meersseman, W.,et al, 2007
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Salvage Therapy for Primary CNS Lymphoma with a Combination of Rituximab and Temozolomide
Neurol 63:901-903, Enting,R.H.,et al, 2004